This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine. The population was relapsed/refractory non-Hodgkin's B-cell lymphoma. The sample size was 33. The intervention was R-GemOx regimen combined with autologous NK cells. The dose of autologous NK cells was body surface area x (2-4) x 109 cells. The course of treatment was once every 14 days. The primary outcome measure was ORR. The duration of assessment was for each treatment cycle, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 3 years, and 5 years of treatment.
Patients with age 15 years to 80 years, with life expectancy greater than 6 months.
Pathologically confirmed non-Hodgkin B-cell lymphoma, confirmed by pathological examination at a grade A class 3 hospital or above, with pathology reported less than 3 years ago.
First diagnosed relapsed/refractory non-Hodgkin's B-cell lymphoma.
ECOG scores were 0 to 2
Presence of bone marrow or/and central nervous system lymphoma.
Patients with less than 5% peripheral blood NK cell percentage and pre-culture failure.
Combined with other malignancies.
Fever of non-disease-related origin within the last 5 days.
Xiangyang No.1 People's Hospital
Lead sponsor
Qingdao Haier Biotechnology Co.,Ltd.
Collaborator